TY - JOUR T1 - Myasthenia gravis: Association of British Neurologists’ management guidelines JF - Practical Neurology JO - Pract Neurol SP - 199 LP - 206 DO - 10.1136/practneurol-2015-001126 VL - 15 IS - 3 AU - Jon Sussman AU - Maria E Farrugia AU - Paul Maddison AU - Marguerite Hill AU - M Isabel Leite AU - David Hilton-Jones Y1 - 2015/06/01 UR - http://pn.bmj.com/content/15/3/199.abstract N2 - Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines. ER -